Reltecimod sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571323

CAS#: 1943755-99-4 (sodium)

Description: Reltecimod, also known as AB-103, NSC-37096, P-2TA, is a CD28 antigen inhibitor potentially for the treatment of necrotizing soft tissue infection.

Chemical Structure

img
Reltecimod sodium
CAS# 1943755-99-4 (sodium)
Instruction

Theoretical Analysis

MedKoo Cat#: 571323
Name: Reltecimod sodium
CAS#: 1943755-99-4 (sodium)
Chemical Formula: C46H71N10NaO15S
Exact Mass: 0.00
Molecular Weight: 1,059.180
Elemental Analysis: C, 52.16; H, 6.76; N, 13.22; Na, 2.17; O, 22.66; S, 3.03

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1943755-99-4 (sodium)   1447799-33-8 (free)  

Synonym: Reltecimod sodium; AB103 sodium; AB 103 sodium; AB-103 sodium

IUPAC/Chemical Name: sodium (S)-3-((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-((S)-1-(D-alanyl-L-seryl)pyrrolidine-2-carboxamido)-4-(methylthio)butanamido)-4-methylpentanamido)-3-methylbutanamido)propanamido)-3-(4-hydroxyphenyl)propanamido)-4-(((R)-1-carboxyethyl)amino)-4-oxobutanoate

InChi Key: GQYCKGDMCOZFKT-CHDMJDELSA-M

InChi Code: InChI=1S/C46H72N10O15S.Na/c1-22(2)18-30(52-39(63)29(15-17-72-8)50-43(67)34-10-9-16-56(34)45(69)33(21-57)54-37(61)24(5)47)42(66)55-36(23(3)4)44(68)48-25(6)38(62)51-31(19-27-11-13-28(58)14-12-27)41(65)53-32(20-35(59)60)40(64)49-26(7)46(70)71;/h11-14,22-26,29-34,36,57-58H,9-10,15-21,47H2,1-8H3,(H,48,68)(H,49,64)(H,50,67)(H,51,62)(H,52,63)(H,53,65)(H,54,61)(H,55,66)(H,59,60)(H,70,71);/q;+1/p-1/t24-,25+,26-,29+,30+,31+,32+,33+,34+,36+;/m1./s1

SMILES Code: CSCC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C(O)=O)C)=O)CC([O-])=O)=O)CC1=CC=C(O)C=C1)=O)C)=O)C(C)C)=O)CC(C)C)=O)NC([C@@H]2CCCN2C([C@@H](NC([C@H](N)C)=O)CO)=O)=O.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,059.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ahn M, Han YH, Park JE, Kim S, Lee WC, Lee SJ, Gunasekaran P, Cheong C, Shin SY Sr, Kim HY, Ryu EK, Murugan RN, Kim NH, Bang JK. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1. J Med Chem. 2015 Jan 8;58(1):294-304. doi: 10.1021/jm501147g. Epub 2014 Nov 5. PubMed PMID: 25347203.

2: LIDDLE HV, THOMAS JM. AB-103 (NSC-37096) IN THE TREATMENT OF BRONCHOGENIC CARCINOMA. Cancer Chemother Rep. 1964 Jul;39:61-5. PubMed PMID: 14201277.

3: MECHL Z, KOLAR V, KONECNY M. THE USE OF THE DRUGS AB 103 AND AB 132 IN THE COMBINED TREATMENT OF TUMOURS OF THE CERVICAL AND PULMONARY REGIONS. Neoplasma. 1964;11:491-8. PubMed PMID: 14220338.

4: NEVINNY-STICKEL HB, DEDERICK MM, HAINES CR, HALL TC. A STUDY OF BENZCARBIMINE (AB-103; NSC-37096) IN PATIENTS WITH VARIOUS MALIGNANCIES. Cancer Chemother Rep. 1963 Dec;33:15-20. PubMed PMID: 14102077.

5: MOERTEL CG, REITEMEIER RJ, HAHN RG. AN EVALUATION OF AB-103 (NSC-37096) IN THE PALLIATIVE MANAGEMENT OF ADVANCED GASTROINTESTINAL CARCINOMA. Cancer Chemother Rep. 1963 Oct;32:97-8. PubMed PMID: 14088841.

6: COPPOLA ED, DEJODE LR, HOWARD JM. Studies of homotransplantation of the kidney in dogs treated with an experimental cancer chemotherapeutic agent (AB-103). Surg Gynecol Obstet. 1962 Jul;115:80-8. PubMed PMID: 13881232.

7: RAZIS DV, AMBRUS JL, ROSS CA, STUTZMAN L, SOKAL JE, REJALI AM, BARDOS TJ. Use of AB-103 (a "dual antagonist") in the treatment of bronchogenic carcinoma. Cancer. 1961 Jul-Aug;14:853-61. PubMed PMID: 13740023.

8: RAZIS DV, AMBRUS JL, ROSS CA, STUTZMAN L, SOKAL JE, REJALI AB. AB-103, a new chemotherapeutic agent in the treatment of bronchogenic carcinoma-a preliminary report. Cancer Chemother Rep. 1960 Nov;9:37-8. PubMed PMID: 13740022.